Current Clinical Trials

Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Phase 3 Study of Tarlatamab Therapy

Who May Qualify:

• Diagnosed with limited-stage small-cell lung cancer
• Completed chemotherapy and radiation
• No disease progression

Purpose: Evaluating treatment after standard therapy.

Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Phase 3 Study of Sacituzumab Govitecan

Who May Qualify:

• Diagnosed with extensive-stage small-cell lung cancer
• Prior platinum-based chemotherapy
• Disease progression

Purpose: Comparing investigational therapy with standard care.

Advanced or Metastatic Non-Squamous NSCLC

Phase 2 Study of ABBV-400 + Budigalimab

Who May Qualify:

• Diagnosed with advanced or metastatic non-small cell lung cancer
• No prior treatment for advanced disease
• No actionable mutations

Purpose: Evaluating combination therapy as a first-line treatment option.

Sickle Cell Disease (SCD)

Phase 3 Study of Crizanlizumab

Who May Qualify:

• Diagnosed with sickle cell disease
• Experienced multiple pain crises

Purpose: Evaluating whether treatment may help reduce pain crises.

Acute Myeloid Leukemia (FLT3-ITD+)

Phase 2 Study of Quizartinib Maintenance Therapy

Who May Qualify:

• Diagnosed with AML (FLT3-ITD+)
• Currently in remission
• No prior stem cell transplant
• Candidate for maintenance therapy

Purpose: Evaluating safety and tolerability of maintenance therapy.